Stocks Health care PHAR
NASDAQ · Health carePharming Group N.V. (PHAR)
Pharming Group N.V. reported revenue of $376.1M in fiscal 2025, up 26.6% from a year earlier. Net income was $2.9M, a net margin of 0.8%. Operating cash flow minus capital spending left $54M of free cash flow in fiscal 2025. At December 31, 2025 it held $145.3M in cash. Its latest periodic report to the SEC is the annual report (foreign issuer, amended) (20-F/A) filed on April 13, 2026.
Key facts about Pharming Group N.V.
- Net worth
- Pharming Group N.V. has a market value (market cap) of $933.7M at the latest share price, and shareholders' equity of $277.1M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $376.1M (+26.6% year on year), with net income of $2.9M.
- Cash flow
- In fiscal 2025 operations brought in $54.7M of cash; after $749K of capital spending, free cash flow was $54M.
- Latest report
- The latest periodic report (annual report (foreign issuer, amended), 20-F/A) was filed with the SEC on April 13, 2026 and covers the period to December 31, 2025. Open on SEC EDGAR
What Pharming Group N.V. does
Pharming Group N.V. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PHAR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $376.1M | $2.9M | $0.00 | $54M |
| 2024 | $297.2M | -$11.8M | -$0.02 | -$2.6M |
| 2023 | $245.3M | -$10.5M | -$0.02 | -$18.7M |
| 2022 | $205.6M | $13.7M | $0.02 | $21.1M |
| 2021 | $198.9M | $16M | $0.02 | $27.1M |
| 2021 | $212.2M | $37.7M | $0.06 | $79M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PHAR ranks in Health care
Latest SEC filings
What Pharming Group N.V. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026
- October 27, 2026
- October 22, 2026
- October 14, 2026
- September 29, 2026
- September 25, 2026
- September 22, 2026
- September 11, 2026
- August 13, 2026
- July 30, 2026
Insider trades
What the people running Pharming Group N.V. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns PHAR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 18 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| MAC Alpha Capital Management, LP | 2,148,144 | new |
| Silverberg Bernstein Capital Management LLC | 41,547 | -3,200 |
| Crossmark Global Holdings, Inc. | 12,463 | new |
| Citadel Advisors LLC | 11,972 | +1,783 |
| Morgan Stanley | 11,500 | +11 |
| SmartHarvest Portfolios, LLC | 10,415 | -382 |
| Knoll Capital Management, LLC | 4,091 | +34 |
| Silver Grove Financial Group, Inc. | 1,071 | new |
| Nalls Sherbakoff Group, LLC | 870 | 0 |
| Global Retirement Partners, LLC | 456 | new |
| Integrated Wealth Concepts LLC | 380 | new |
| Bnp Paribas Financial Markets | 300 | -100 |
| Optiver Holding B.V. | 305 | new |
| NewEdge Advisors, LLC | 187 | -1,963 |
| UBS Group AG | 39 | new |
| Osaic Holdings, Inc. | 16 | -112 |
| Larson Financial Group LLC | 7 | -336 |
| Caitong International Asset Management Co., Ltd | 1 | new |
Insiders
Questions about PHAR
What does Pharming Group N.V. do?
Pharming Group N.V. is a company in the Health care sector, listed on NASDAQ as PHAR. Its shares trade on NASDAQ under the ticker PHAR.
What is Pharming Group N.V.'s net worth?
Pharming Group N.V. has a market value (market cap) of $933.7M at the latest share price, and shareholders' equity of $277.1M on its balance sheet at December 31, 2025. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Pharming Group N.V. profitable?
Yes. In fiscal 2025 it reported net income of $2.9M on revenue of $376.1M, a net margin of 0.8%.
How much revenue does Pharming Group N.V. make?
In fiscal 2025 Pharming Group N.V. reported revenue of $376.1M. That is 26.6% more than a year earlier.
When did Pharming Group N.V. last report?
Its most recent periodic report is the annual report (foreign issuer, amended) (20-F/A) filed on April 13, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from November 6, 2026.
Similar companies
Compare PHAR with
Follow PHAR
Get an email when Pharming Group N.V. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Pharming Group N.V. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.